Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cytosorbents Corporation (CTSO : NSDQ)

• Company Description    CytoSorbents Corporation is a therapeutic medical device company. It develops adsorbent polymer technology for applications in the medical field, primarily to provide blood purification for the treatment of acute and chronic health complications associated with blood toxicity. The Company's product include CytoSorb, which filters cytokines and treat potentially fatal cytokine storm and BetaSorb, which remove beta2-microglobulin from the blood of patients suffering from chronic kidney failure. CytoSorbents Corporation is headquartered in Monmouth Junction, New Jersey. Number of Employees: 149

• Price / Volume Information    Yesterday's Closing Price: $0.94 Daily Weekly Monthly 20 Day Moving Average: 117,967 shares Shares Outstanding: 62.76 (millions) Market Capitalization: $58.90 (millions) Beta: 1.28 52 Week High: $1.61 52 Week Low: $0.71 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -17.68% -19.12% 12 Week -19.09% -26.51% Year To Date 3.13% -6.47%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 305 COLLEGE ROAD EAST - PRINCETON,NJ 08540 USA ph: 732-329-8885 fax: 732-329-8650 ir@cytosorbents.com http://www.cytosorbents.com

• General Corporate Information    Officers Phillip P. Chan - Chief Executive Officer Michael G. Bator - Chairman of the Board Peter J. Mariani - Chief Financial Officer Alan D. Sobel - Director Edward R. Jones - Director Peer Information Cytosorbents Corporation (BJCT) Cytosorbents Corporation (CADMQ) Cytosorbents Corporation (APNO) Cytosorbents Corporation (UPDC) Cytosorbents Corporation (IMTIQ) Cytosorbents Corporation (CYGN) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED PRODUCTS Sector: Medical CUSIP: 23283X206 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 62.76 Most Recent Split Date: 12.00 (0.04:1) Beta: 1.28 Market Capitalization: $58.90 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.05 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.16 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 5.07 Price/Cash Flow: - Price / Sales: 1.60 EPS Growth vs. Year Ago Period: 37.50% vs. Previous Quarter: 16.67% Sales Growth vs. Year Ago Period: -2.81% vs. Previous Quarter: 10.20% ROE 06/30/25 - -111.97 03/31/25 - -105.04 12/31/24 - -115.30 ROA 06/30/25 - -29.00 03/31/25 - -29.18 12/31/24 - -35.22 Current Ratio 06/30/25 - 2.34 03/31/25 - 2.61 12/31/24 - 2.20 Quick Ratio 06/30/25 - 1.96 03/31/25 - 2.30 12/31/24 - 1.92 Operating Margin 06/30/25 - -38.12 03/31/25 - -39.14 12/31/24 - -45.08 Net Margin 06/30/25 - -25.58 03/31/25 - -41.77 12/31/24 - -53.38 Pre-Tax Margin 06/30/25 - -31.34 03/31/25 - -47.90 12/31/24 - -62.96 Book Value 06/30/25 - 0.19 03/31/25 - 0.23 12/31/24 - 0.20 Inventory Turnover 06/30/25 - 3.57 03/31/25 - 3.27 12/31/24 - 2.98 Debt-to-Equity 06/30/25 - 1.24 03/31/25 - 0.98 12/31/24 - 1.26 Debt-to-Capital 06/30/25 - 55.38 03/31/25 - 49.38 12/31/24 - 55.75

Powered by Zacks Investment Research ©